STOCK TITAN
  1. Home
  2. News
  3. CMPS

COMPASS Pathways Plc American Depository Shares - CMPS STOCK NEWS

Welcome to our dedicated page for COMPASS Pathways Plc American Depository Shares news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on COMPASS Pathways Plc American Depository Shares stock.

Compass Pathways Plc (Nasdaq: CMPS) is a biotechnology company at the forefront of mental health innovation, dedicated to accelerating patient access to evidence-based therapies. Headquartered in London, UK, with offices in New York and San Francisco, Compass is pioneering a new model of psilocybin therapy, specifically targeting treatment-resistant depression (TRD). The company’s flagship product, a proprietary high-purity polymorphic crystalline formulation of synthetic psilocybin known as COMP360, is at the core of their therapeutic approach.

Compass Pathways has made significant strides in mental health care by combining psilocybin treatment with psychological support. This dual approach is designed to provide comprehensive care for patients unresponsive to standard treatments. COMP360 has been designated a 'Breakthrough Therapy' by the U.S. Food and Drug Administration (FDA) and also received the Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD.

The company's research is supported by robust clinical trials. Compass has commenced a Phase 3 clinical program for COMP360, making it the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previous Phase 2b studies have shown that a single 25mg dose of COMP360 can significantly improve depressive symptoms with sustained effects over weeks. In addition to TRD, Compass is exploring the potential of COMP360 for treating post-traumatic stress disorder (PTSD) and anorexia nervosa through ongoing Phase 2 clinical trials.

Recent collaborations with leading healthcare institutions like Hackensack Meridian Health and Journey Clinical are aimed at understanding and optimizing the delivery models for COMP360, should it receive FDA approval. These partnerships also include exploration into therapist training and care reimbursement processes to ensure that the treatment can be integrated smoothly into existing healthcare systems.

Financially, Compass Pathways remains committed to transparency and regular updates to investors through various platforms including their website, social media, and investor relations channels. The company's vision is to create a world where mental well-being is within reach for all.

For the latest news and updates on Compass Pathways, visit www.compasspathways.com.

News

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) reports financial results for Q4 2023, with a cash position of $220.2 million as of December 31, 2023. The company's COMP360 phase 3 pivotal program is progressing, with top-line data expected in Q4 2024 and mid-2025. Teri Loxam appointed as Chief Financial Officer on March 1, 2024. Net loss for 2023 was $118.5 million, with R&D expenses increasing to $87.5 million. Cash and cash equivalents at $220.2 million as of December 31, 2023, with $31.4 million net cash raised in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.98%
Tags
earnings
-
News

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) and Hackensack Meridian Health have announced a research collaboration agreement to inform the delivery model design of investigational COMP360 psilocybin treatment for treatment-resistant depression. The collaboration aims to improve health outcomes and patient experiences. COMP360 is Compass's proprietary formulation of synthetic psilocybin, administered with psychological support. Hackensack Meridian Health, a leading not-for-profit healthcare organization, will leverage its extensive experience in treating depression to inform how new mental health treatments may be accessed by patients in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
News

Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) and Greenbrook TMS Inc. (NASDAQ: GBNH) have entered into a three-year research collaboration to explore scalable, commercial delivery models for COMP360 psilocybin treatment upon FDA approval. COMP360 has been designated a 'Breakthrough Therapy' by the FDA for treatment-resistant depression (TRD). The collaboration aims to improve patient care experience and therapist needs, as well as investigate the potential use of digital tools within Greenbrook TMS's care pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.97%
Tags
none
News

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) announced positive initial safety findings for investigational COMP360 psilocybin treatment in a phase 2 clinical trial for post-traumatic stress disorder (PTSD). The 24-hour data readout showed that COMP360 was well-tolerated with no serious adverse events. The study is being conducted in the UK and US, with safety and efficacy data expected to be announced in spring 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.87%
Tags
clinical trial
-
News

Compass Pathways appoints Teri Loxam as Chief Financial Officer

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) has appointed Teri Loxam as Chief Financial Officer (CFO), effective March 2024. Teri brings deep strategic experience from publicly traded companies in the pharmaceutical and biotechnology sectors. She will be based in the company’s New York City office.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
management
-
News

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) announced the publication of a paper in JAMA Psychiatry demonstrating the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder. The study conducted by Dr. Scott Aaronson at Sheppard Pratt, Baltimore, and funded by Compass, showed that all participants had lower MADRS scores with a mean change from baseline of -24.0 points at week 3, with 12 participants meeting the response criteria and 11 meeting the remission criteria. The study also reported no increase in the suicidality score, no manic symptoms, and no unexpected adverse events or difficulties with the dosing sessions reported throughout the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none
News

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

Rhea-AI Summary
Compass Pathways plc (Nasdaq: CMPS) announced the initiation of the UK component of its phase 3 program of investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The research will take place in multiple sites in the UK, including at the Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. The phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
clinical trial
-
News

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary
COMPASS Pathways reports financial results for Q3 2023, with a cash position of $248.0 million as of September 30, 2023. The COMP360 phase 3 program is ongoing, and top-line data for COMP005 is expected in summer 2024. The company also expects top-line data for its phase 2 study in PTSD by the end of this year. COMPASS secured up to $285 million in private placement financing. The CEO expressed confidence in the clinical programs and pre-commercial work for a potential new drug application filing with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
earnings
-
News

COMPASS Pathways announces CFO transition

Rhea-AI Summary
COMPASS Pathways announces CFO departure and appointment of interim CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
none
News

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

Rhea-AI Summary
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
management

FAQ

What is the current stock price of COMPASS Pathways Plc American Depository Shares (CMPS)?

The current stock price of COMPASS Pathways Plc American Depository Shares (CMPS) is $4.66 as of November 20, 2024.

What is the market cap of COMPASS Pathways Plc American Depository Shares (CMPS)?

The market cap of COMPASS Pathways Plc American Depository Shares (CMPS) is approximately 325.7M.

What is Compass Pathways Plc?

Compass Pathways Plc is a biotechnology company focused on accelerating patient access to innovative mental health treatments, particularly using psilocybin therapy for treatment-resistant depression.

What is COMP360?

COMP360 is Compass Pathways' proprietary high-purity polymorphic crystalline formulation of synthetic psilocybin, used in conjunction with psychological support to treat mental health conditions like treatment-resistant depression.

What designations has COMP360 received?

COMP360 has been designated as a 'Breakthrough Therapy' by the FDA and received an Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression.

What clinical trials are currently underway for COMP360?

Compass Pathways has commenced Phase 3 clinical trials for COMP360 in treatment-resistant depression and is conducting Phase 2 studies for post-traumatic stress disorder (PTSD) and anorexia nervosa.

Who are Compass Pathways' partners in mental health research?

Compass Pathways has partnered with several institutions, including Hackensack Meridian Health and Journey Clinical, to improve the delivery and integration of COMP360 therapy into existing healthcare systems.

Where is Compass Pathways headquartered?

Compass Pathways is headquartered in London, UK, with additional offices in New York and San Francisco.

How does Compass Pathways communicate with its investors?

Compass Pathways regularly updates investors via their website, investor relations site, and social media platforms, providing access to press releases, SEC filings, and conference call webcasts.

What was the outcome of the Phase 2b study for COMP360?

The Phase 2b study showed that a single 25mg dose of COMP360 psilocybin resulted in a statistically significant and clinically relevant improvement in depressive symptoms after three weeks.

What is the focus of Compass Pathways' latest research collaborations?

The latest research collaborations focus on understanding patient pathways, therapist training, and the integration of COMP360 into healthcare delivery models to ensure effective and scalable treatment options.

What is the mission of Compass Pathways?

Compass Pathways aims to improve the lives of people suffering from mental health challenges through innovative, evidence-based therapies like psilocybin treatment.

Stock CMPS logo
COMPASS Pathways Plc American Depository Shares

Nasdaq:CMPS

CMPS Rankings

#3452 Ranked by Market Cap
N/A Ranked by Dividends

CMPS Stock Data

325.68M
53.27M
22.15%
48.38%
7.96%
Medical Care Facilities
Pharmaceutical Preparations
Link
United States of America
CHESIRE